Hajime Uno

Research Scientist
This email address is being protected from spambots. You need JavaScript enabled to view it.



Dr. Hajime Uno's research activities include statistical support for clinical trials and
laboratory study in collaboration with investigators from the Eastern Cooperative Oncology Group's Myeloma Committee and Harvard University Center for AIDS research. His methodological research focuses on evaluating prediction models for clinical outcomes based on standard clinical parameter and biomarkers and on assessing incremental value of new risk scoring systems.



Dr. Uno worked for Takeda, one of pharmaceutical company in Japan, as a statistician to support clinical trials for new drug approval, from 1994 to 2003. The disease area he worked on there include breast cancer, diabetes, and cardiovascular disease and so on. In 2003, he received his PhD in Biostatistics from Kitasato University Graduate School, Tokyo, Japan. He then did a postdoc for a few years at Harvard School of Public Health under the direction of Profs. LJ Wei and Steve Lagakos. He then went back to Japan and joined the faculty of Kitasato University, and then visited Harvard again and became a Research Scientist in the Department of Biostatistics and Computational Biology at Dana-Farber Cancer Institute in 2008. His collaborative work at Dana-Farber is mainly in multiple myeloma studies with the Eastern Cooperative Oncology Group and laboratory study with investigators from Center for AIDS research.


Select Publication

Kastrinos F, Uno H, Ukaegbu C, Alvero C, McFarland A, Yurgelun MB, Kulke MH, Schrag D, Meyerhardt JA, Fuchs CS, Mayer RJ, Ng K, Steyerberg EW, Syngal S. Development and Validation of the PREMM(5) Model for Comprehensive Risk Assessment of Lynch Syndrome. J Clin Oncol. 2017 May 10:JCO2016696120.


Dutta A, Uno H, Holman A, Lorenz DR, Gabuzda D. Racial differences in prostate cancer risk in young HIV-positive and HIV-negative men: a prospective cohort study. Cancer Causes Control. 2017 Apr 27.


Lorenz DR, Dutta A, Mukerji SS, Holman A, Uno H, Gabuzda D. Marijuana use impacts midlife cardiovascular events in HIV-infected men. Clin Infect Dis. 2017 Apr 25.


Dutta A, Uno H, Holman A, Lorenz DR, Wolinsky SM, Gabuzda D. Long-term nitrite inhalant exposure and cancer risk in MSM. AIDS. 2017 May 15;31(8):1169-1180.


Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, Ukaegbu CI, Brais LK, McNamara PG, Mayer RJ, Schrag D, Meyerhardt JA, Ng K, Kidd J, Singh N, Hartman AR, Wenstrup RJ, Syngal S. Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. J Clin Oncol. 2017 Apr 1;35(10):1086-1095.


Davoli T, Uno H, Wooten EC, Elledge SJ. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science. 2017 Jan 20;355(6322).


Zeidan AM, Davidoff AJ, Long JB, Hu X, Wang R, Ma X, Gross CP, Abel GA, Huntington SF, Podoltsev NA, Hajime U, Prebet T, Gore SD. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. Br J Haematol. 2016 Dec;175(5):829-840.


Hasegawa T, Uno H, Wei LJ. Safety Study of Salmeterol in Asthma in Adults. N Engl J Med. 2016 Sep 15;375(11):1097.


Hasegawa T, Uno H, Wei LJ. How To Summarize the Safety Profile of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy? J Clin Oncol. 2016 Aug 9.


Punglia RS, Cronin AM, Uno H, Stout NK, Ozanne EM, Greenberg CC, Frank ES, Schrag D. Association of Regional Intensity of Ductal Carcinoma In Situ Treatment With Likelihood of Breast Preservation. JAMA Oncol. 2017 Jan 1;3(1):101-104.


Related Links

Personal Page

Eastern Cooperative Oncology Group (ECOG)

Harvard University Center for AIDS Research (CFAR)

Department of Biostatstics, Harvard University